Want to see AU:LDX full AI Analyst Report?
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)5.63M
Market Cap
AU$94.48M
Enterprise ValueAU$225.36
Total Cash (Recent Filing)AU$3.00M
Total Debt (Recent Filing)AU$11.85M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Sep 01, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding944,820,400
10 Day Avg. Volume3,659,446
30 Day Avg. Volume5,628,467
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.96
Price to Sales (P/S)0.97
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside-21.88% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$33.20M
Bulls Say, Bears Say
Bulls Say
Distribution Agreement (PHASE)A six-year exclusive U.S. PHASE distribution deal with a USD 317M minimum provides durable revenue visibility and market access. It materially de-risks U.S. commercialization execution for multiple years and supports scale-up planning and partner-led sales effort over the medium term.
Reimbursement CoverageCMS reimbursement at USD 41.38/test and agreement from seven MACs creates a structurally stronger economic proposition for clinicians. Durable reimbursement reduces adoption friction, supports sustainable per-test pricing and revenue per unit, and improves long-term commercial uptake.
High Gross Margins & Product MixSustained gross margins (~68% company, >60% for FebriDx) imply strong unit economics and pricing power versus peers. High product margins support operating leverage as volumes scale, improving the odds of moving toward profitability when commercial volumes from the U.S. agreement materialize.
Bears Say
CLIA Waiver DependencyThe CLIA waiver is a structural gating item: without it, the company cannot fully access point-of-care clinic volumes that drive the PHASE agreement’s economics. This conditionality creates sustained execution risk over the coming months and delays realization of contracted sales.
Declining Revenue & Ongoing LossesA multi-year trend of revenue decline and persistent negative margins undermines internal funding capacity and operational resilience. Continued losses reduce flexibility to invest in manufacturing or commercial scale and increase reliance on external financing or non-dilutive grants.
Leverage & Cash Flow StrainHigh leverage (debt/equity ~1.13) combined with historically negative operating and free cash flow constrains strategic options. The company may need additional capital to fund manufacturing scale beyond year two of PHASE, risking expensive dilution or covenant pressures that affect long-term plans.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.08 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$94.48M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 25 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate is -0.01.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 944,820,400 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.843%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (-21.88% Downside)
AU$0.25 (-21.88% Downside)
Blogger Sentiment
Bullish
AU:LDX Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$61.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
551.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.05%
Trailing 12-Months
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. (LDX) is a diagnostics company focused on developing and commercialising point-of-care (rapid) diagnostic tests, including antigen-based tests that use immunoassay technologies. The company operates in the in-vitro diagnostics sector and targets applications such as infectious disease and other rapid testing settings, supplying test products and related diagnostic solutions to healthcare and other testing markets.
LDX Stock 12 Month Forecast
Average Price Target
AU$0.25
▼(-21.88% Downside)
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―







